Lacidipine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Lacidipine
Accession Number
DB09236
Type
Small Molecule
Groups
Approved
Description

Lacidipine is a calcium channel blocker. It is available as tablets containing 2 or 4 mg.

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Lacipil (GSK) / Motens (Boehringer Ingelheim)
Categories
UNII
260080034N
CAS number
103890-78-4
Weight
Average: 455.551
Monoisotopic: 455.230787787
Chemical Formula
C26H33NO6
InChI Key
GKQPCPXONLDCMU-CCEZHUSRSA-N
InChI
InChI=1S/C26H33NO6/c1-8-31-24(29)21-16(3)27-17(4)22(25(30)32-9-2)23(21)19-13-11-10-12-18(19)14-15-20(28)33-26(5,6)7/h10-15,23,27H,8-9H2,1-7H3/b15-14+
IUPAC Name
3,5-diethyl 4-{2-[(1E)-3-(tert-butoxy)-3-oxoprop-1-en-1-yl]phenyl}-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C)C(=O)OCC

Pharmacology

Indication

For the treatment of hypertension.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Lacidipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Lacidipine.Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Lacidipine.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Lacidipine.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Lacidipine is combined with Aldesleukin.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Lacidipine.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of Lacidipine.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Lacidipine.Approved, Withdrawn
AmbrisentanLacidipine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineLacidipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Lacidipine is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Lacidipine.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Lacidipine.Approved
AmobarbitalThe metabolism of Lacidipine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Lacidipine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Lacidipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Lacidipine is combined with Amyl Nitrite.Approved
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Lacidipine.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Lacidipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Lacidipine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Lacidipine.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Lacidipine.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Lacidipine.Approved
AtenololAtenolol may increase the hypotensive activities of Lacidipine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Lacidipine is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Lacidipine is combined with Atosiban.Approved
Atracurium besylateLacidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Lacidipine is combined with Azilsartan medoxomil.Approved
BaclofenBaclofen may increase the hypotensive activities of Lacidipine.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Lacidipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Lacidipine.Experimental
BarbitalThe metabolism of Lacidipine can be increased when combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Lacidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Lacidipine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Lacidipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Lacidipine.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Lacidipine.Approved
BepridilBepridil may increase the hypotensive activities of Lacidipine.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Lacidipine.Approved
BethanidineBethanidine may increase the hypotensive activities of Lacidipine.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Lacidipine.Experimental
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Lacidipine.Approved
BimatoprostBimatoprost may increase the hypotensive activities of Lacidipine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Lacidipine.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Lacidipine.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Lacidipine.Approved, Investigational
BQ-123Lacidipine may increase the hypotensive activities of BQ-123.Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when 1,6,7,8,9,11A,12,13,14,14A-DECAHYDRO-1,13-DIHYDROXY-6-METHYL-4H-CYCLOPENT[F]OXACYCLOTRIDECIN-4-ONE is combined with Lacidipine.Experimental
BretyliumBretylium may increase the hypotensive activities of Lacidipine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Lacidipine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Lacidipine.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lacidipine.Approved, Investigational
BucindololBucindolol may increase the hypotensive activities of Lacidipine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Lacidipine is combined with Bumetanide.Approved
BunazosinBunazosin may increase the hypotensive activities of Lacidipine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lacidipine.Approved, Investigational
BupranololBupranolol may increase the hypotensive activities of Lacidipine.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Lacidipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Lacidipine.Approved
CadralazineCadralazine may increase the hypotensive activities of Lacidipine.Experimental
CafedrineLacidipine may increase the hypotensive activities of Cafedrine.Investigational
CalciumThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Carbonate.Approved
Calcium CitrateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium laevulateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Phosphate.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Lacidipine is combined with Canagliflozin.Approved
CandesartanCandesartan may increase the hypotensive activities of Lacidipine.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Lacidipine.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Lacidipine.Experimental
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Lacidipine.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Lacidipine.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Lacidipine.Approved
CarbomycinThe metabolism of Lacidipine can be decreased when combined with Carbomycin.Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Lacidipine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Lacidipine.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Lacidipine.Approved, Investigational
CaseinThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Lacidipine.Approved
CeliprololCeliprolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
CerivastatinThe risk or severity of adverse effects can be increased when Lacidipine is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Lacidipine.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Lacidipine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lacidipine.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Lacidipine.Approved
CicletanineLacidipine may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Lacidipine.Approved, Investigational
CilazaprilCilazapril may increase the hypotensive activities of Lacidipine.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Lacidipine.Approved
CimetidineThe serum concentration of Lacidipine can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe metabolism of Lacidipine can be decreased when combined with Clarithromycin.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Lacidipine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Lacidipine.Approved, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Lacidipine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Lacidipine.Approved, Nutraceutical
CloranololLacidipine may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Lacidipine.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Lacidipine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Lacidipine.Approved, Investigational
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Lacidipine.Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Lacidipine.Approved
CyclopenthiazideLacidipine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Lacidipine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Lacidipine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Lacidipine is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Lacidipine is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Lacidipine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Lacidipine.Approved
DelaprilLacidipine may increase the hypotensive activities of Delapril.Experimental
DeserpidineLacidipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Lacidipine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Lacidipine.Approved
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Lacidipine.Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Lacidipine is combined with Diclofenamide.Approved
diethylnorsperminediethylnorspermine may increase the hypotensive activities of Lacidipine.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Lacidipine.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Lacidipine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Lacidipine is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Lacidipine is combined with Dipyridamole.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Lacidipine.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Lacidipine.Approved
DuloxetineLacidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Lacidipine.Approved
EfavirenzThe serum concentration of Lacidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Lacidipine.Approved
EfonidipineEfonidipine may increase the hypotensive activities of Lacidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Lacidipine is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
EnalaprilatLacidipine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Lacidipine.Experimental
EpanololLacidipine may increase the hypotensive activities of Epanolol.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Lacidipine is combined with Eplerenone.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Lacidipine.Approved
EprosartanEprosartan may increase the hypotensive activities of Lacidipine.Approved
ErythromycinThe metabolism of Lacidipine can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Lacidipine is combined with Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Lacidipine is combined with Etacrynic acid.Approved
FelodipineFelodipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Lacidipine.Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Lacidipine.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Lacidipine.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Lacidipine.Approved
FluconazoleThe serum concentration of Lacidipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Lacidipine.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Lacidipine.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Lacidipine is combined with Fluvastatin.Approved
FosinoprilFosinopril may increase the hypotensive activities of Lacidipine.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Lacidipine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Lacidipine is combined with Furosemide.Approved, Vet Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Lacidipine.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Lacidipine.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Lacidipine.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Lacidipine.Approved
GuanazodineLacidipine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Lacidipine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Lacidipine.Approved, Investigational
GuanoclorLacidipine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzLacidipine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanLacidipine may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Lacidipine.Experimental
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Lacidipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Lacidipine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Lacidipine.Experimental
HexamethoniumHexamethonium may increase the hypotensive activities of Lacidipine.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Lacidipine.Approved
HexobarbitalThe metabolism of Lacidipine can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Lacidipine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Lacidipine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Lacidipine.Approved
IloprostIloprost may increase the hypotensive activities of Lacidipine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Lacidipine.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Lacidipine.Approved
IndapamideIndapamide may increase the hypotensive activities of Lacidipine.Approved
IndenololIndenolol may increase the hypotensive activities of Lacidipine.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Lacidipine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Lacidipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Lacidipine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Lacidipine.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Lacidipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Lacidipine.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Lacidipine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Lacidipine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Lacidipine.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Lacidipine.Approved, Investigational
JosamycinThe metabolism of Lacidipine can be decreased when combined with Josamycin.Approved
KetanserinKetanserin may increase the hypotensive activities of Lacidipine.Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Lacidipine.Approved, Investigational
KitasamycinThe metabolism of Lacidipine can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Lacidipine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Lacidipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Levobupivacaine.Approved
LevodopaLacidipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Lacidipine is combined with Levosimendan.Approved, Investigational
LinsidomineLacidipine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Lacidipine.Approved, Investigational
LofexidineLofexidine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Lacidipine.Approved
LovastatinThe risk or severity of adverse effects can be increased when Lacidipine is combined with Lovastatin.Approved, Investigational
MacitentanLacidipine may increase the hypotensive activities of Macitentan.Approved
Magnesium HydroxideThe risk or severity of adverse effects can be increased when Lacidipine is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Lacidipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Lacidipine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Lacidipine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineLacidipine may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Lacidipine is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Lacidipine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Lacidipine.Approved
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Lacidipine.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Lacidipine is combined with Methazolamide.Approved
MethohexitalThe metabolism of Lacidipine can be increased when combined with Methohexital.Approved
MethoserpidineLacidipine may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Lacidipine is combined with Methyclothiazide.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Lacidipine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Lacidipine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Lacidipine.Approved, Investigational
MethylphenobarbitalThe metabolism of Lacidipine can be increased when combined with Methylphenobarbital.Approved
MetipranololMetipranolol may increase the hypotensive activities of Lacidipine.Approved
MetolazoneMetolazone may increase the hypotensive activities of Lacidipine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
MetyrosineLacidipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Lacidipine.Experimental
MibefradilMibefradil may increase the hypotensive activities of Lacidipine.Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Lacidipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Lacidipine.Approved, Investigational, Vet Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Lacidipine.Approved
MinaprineMinaprine may increase the hypotensive activities of Lacidipine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Lacidipine.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Lacidipine.Investigational
MivacuriumLacidipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Lacidipine.Approved
MoexiprilMoexipril may increase the hypotensive activities of Lacidipine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Lacidipine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Lacidipine.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Morphine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Lacidipine.Approved
MuzolimineLacidipine may increase the hypotensive activities of Muzolimine.Experimental
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Lacidipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Lacidipine is combined with Nabilone.Approved, Investigational
NadololNadolol may increase the hypotensive activities of Lacidipine.Approved
NafcillinThe metabolism of Lacidipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Lacidipine.Approved
NaftopidilLacidipine may increase the hypotensive activities of Naftopidil.Investigational
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Lacidipine.Approved
NebivololNebivolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Lacidipine is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Lacidipine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Lacidipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Lacidipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Nifedipine.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Lacidipine.Experimental
NiguldipineLacidipine may increase the hypotensive activities of Niguldipine.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Lacidipine.Investigational
NilvadipineNilvadipine may increase the hypotensive activities of Lacidipine.Approved
NimodipineNimodipine may increase the hypotensive activities of Lacidipine.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Lacidipine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Lacidipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Lacidipine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Lacidipine is combined with Nitroglycerin.Approved, Investigational
NitroprussideLacidipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Lacidipine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Lacidipine.Approved, Vet Approved
ObinutuzumabLacidipine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Lacidipine.Withdrawn
OleandomycinThe metabolism of Lacidipine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanOlmesartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Lacidipine.Investigational
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Lacidipine.Experimental
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Lacidipine.Approved
OxprenololOxprenolol may increase the hypotensive activities of Lacidipine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Lacidipine is combined with Paclitaxel.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Lacidipine.Investigational
PapaverineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Papaverine.Approved
PargylinePargyline may increase the hypotensive activities of Lacidipine.Approved
PenbutololPenbutolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Lacidipine.Approved
PentobarbitalThe metabolism of Lacidipine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Lacidipine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Lacidipine.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Lacidipine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Lacidipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Lacidipine.Withdrawn
PhenobarbitalThe metabolism of Lacidipine can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Lacidipine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Lacidipine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Lacidipine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Lacidipine.Approved, Vet Approved
PinacidilPinacidil may increase the hypotensive activities of Lacidipine.Withdrawn
PindololPindolol may increase the hypotensive activities of Lacidipine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Lacidipine is combined with Pipamperone.Approved
PirlindolePirlindole may increase the hypotensive activities of Lacidipine.Approved
PitavastatinThe risk or severity of adverse effects can be increased when Lacidipine is combined with Pitavastatin.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Lacidipine.Withdrawn
PolythiazidePolythiazide may increase the hypotensive activities of Lacidipine.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Lacidipine.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Lacidipine is combined with Pramipexole.Approved, Investigational
PravastatinThe risk or severity of adverse effects can be increased when Lacidipine is combined with Pravastatin.Approved
PrazosinPrazosin may increase the hypotensive activities of Lacidipine.Approved
PrimidoneThe metabolism of Lacidipine can be increased when combined with Primidone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Lacidipine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololLacidipine may increase the hypotensive activities of Propranolol.Approved, Investigational
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Lacidipine.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Quetiapine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Lacidipine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Lacidipine.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Lacidipine.Experimental
RamiprilRamipril may increase the hypotensive activities of Lacidipine.Approved
RapacuroniumLacidipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Lacidipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Lacidipine is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Lacidipine.Approved
RescinnamineLacidipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Lacidipine.Approved
RifabutinThe serum concentration of Lacidipine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Lacidipine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Lacidipine can be decreased when it is combined with Rifapentine.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Lacidipine.Investigational
RiociguatLacidipine may increase the hypotensive activities of Riociguat.Approved
RisperidoneLacidipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabLacidipine may increase the hypotensive activities of Rituximab.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Lacidipine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Ropivacaine.Approved
RosuvastatinThe risk or severity of adverse effects can be increased when Lacidipine is combined with Rosuvastatin.Approved
RotigotineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Lacidipine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Lacidipine.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Lacidipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Lacidipine.Approved, Vet Approved
SaprisartanSaprisartan may increase the hypotensive activities of Lacidipine.Experimental
SecobarbitalThe metabolism of Lacidipine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Lacidipine.Approved, Investigational, Vet Approved
SelexipagLacidipine may increase the hypotensive activities of Selexipag.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Lacidipine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Lacidipine is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Lacidipine.Approved, Investigational
SilodosinSilodosin may increase the hypotensive activities of Lacidipine.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Lacidipine is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Lacidipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Lacidipine.Approved, Investigational
SitaxentanLacidipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Lacidipine is combined with Sodium Nitrite.Approved
SolithromycinThe metabolism of Lacidipine can be decreased when combined with Solithromycin.Investigational
SotalolThe risk or severity of adverse effects can be increased when Lacidipine is combined with Sotalol.Approved
SpiraprilSpirapril may increase the hypotensive activities of Lacidipine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Lacidipine is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Lacidipine is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Lacidipine is combined with Sufentanil.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Lacidipine.Approved
TadalafilTadalafil may increase the antihypertensive activities of Lacidipine.Approved, Investigational
TalinololLacidipine may increase the hypotensive activities of Talinolol.Investigational
TamsulosinTamsulosin may increase the hypotensive activities of Lacidipine.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Lacidipine.Approved
TelithromycinThe metabolism of Lacidipine can be decreased when combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Lacidipine.Experimental, Investigational
TerazosinTerazosin may increase the hypotensive activities of Lacidipine.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Lacidipine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Lacidipine.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Lacidipine.Approved, Investigational
TetrahydropalmatineLacidipine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Lacidipine is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineLacidipine may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThe metabolism of Lacidipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Lacidipine can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Thioridazine.Withdrawn
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Lacidipine.Approved
TiboloneTibolone may increase the hypotensive activities of Lacidipine.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Lacidipine.Withdrawn
TimololTimolol may increase the hypotensive activities of Lacidipine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Lacidipine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Tizanidine.Approved
TolazolineTolazoline may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Lacidipine is combined with Tolcapone.Approved, Withdrawn
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Lacidipine.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Lacidipine.Approved, Vet Approved
TolonidineLacidipine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Lacidipine.Approved
TorasemideTorasemide may increase the hypotensive activities of Lacidipine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Lacidipine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Lacidipine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Lacidipine.Approved
TravoprostTravoprost may increase the hypotensive activities of Lacidipine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Lacidipine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Lacidipine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Lacidipine is combined with Triamterene.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Lacidipine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Lacidipine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Lacidipine.Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Lacidipine.Approved, Investigational
TylosinThe metabolism of Lacidipine can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Lacidipine is combined with Ubidecarenone.Experimental
UdenafilUdenafil may increase the antihypertensive activities of Lacidipine.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Lacidipine.Approved
UrapidilUrapidil may increase the hypotensive activities of Lacidipine.Investigational
ValsartanValsartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Lacidipine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Lacidipine is combined with Verapamil.Approved
VincamineLacidipine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineLacidipine may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Lacidipine.Approved, Investigational
XipamideLacidipine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Lacidipine.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Lacidipine.Approved, Vet Approved
ZofenoprilLacidipine may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Lacidipine synthesis: C. Semeraro et al., DE 3529997; eidem, U.S. Patent 4,801,599 (1986, 1989 both to Glaxo).

General References
Not Available
External Links
KEGG Drug
D04657
PubChem Compound
5311217
PubChem Substance
310265140
ChemSpider
4470736
ChEBI
135737
ChEMBL
CHEMBL460291
Wikipedia
Lacidipine
ATC Codes
C08CA09 — Lacidipine
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers4
2CompletedTreatmentAngina Pectoris1
3CompletedTreatmentHypertensive1
4CompletedTreatmentHypertension,Essential / Type 2 Diabetes Mellitus1
4CompletedTreatmentHypertensive2
Not AvailableCompletedNot AvailableHypertensive1
Not AvailableTerminatedNot AvailableHypertensive1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00224 mg/mLALOGPS
logP5.18ALOGPS
logP4.19ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)19.47ChemAxon
pKa (Strongest Basic)-6.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area90.93 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity129.91 m3·mol-1ChemAxon
Polarizability49.74 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00fr-0000900000-2964b6b69c71aeda6088
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0169400000-672099fb92e2023950eb

Taxonomy

Description
This compound belongs to the class of organic compounds known as cinnamic acid esters. These are compound containing an ester derivative of cinnamic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Cinnamic acids and derivatives
Sub Class
Cinnamic acid esters
Direct Parent
Cinnamic acid esters
Alternative Parents
Tricarboxylic acids and derivatives / Dihydropyridinecarboxylic acids and derivatives / Styrenes / Fatty acid esters / Vinylogous amides / Enoate esters / Enamines / Dialkylamines / Azacyclic compounds / Organic oxides
show 2 more
Substituents
Cinnamic acid ester / Dihydropyridinecarboxylic acid derivative / Tricarboxylic acid or derivatives / Styrene / Dihydropyridine / Fatty acid ester / Monocyclic benzene moiety / Fatty acyl / Benzenoid / Hydropyridine
show 18 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 23, 2015 10:33 / Updated on October 02, 2017 06:14